12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Forxiga dapagliflozin regulatory update

The U.K.'s NICE said in draft guidance that it was "unable to recommend" the use of Forxiga dapagliflozin from Bristol-Myers Squibb and AstraZeneca as an add-on therapy to treat Type II diabetes. The committee said there was "significant uncertainty" about the validity of meta-analyses showing the clinical effectiveness of Forxiga compared to active comparators in combination therapies. The committee also said it could not "adequately replicate" the partners' economic model, which showed Forxiga had an incremental cost-effectiveness ratio (ICER)...

Read the full 371 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >